Corrigendum

Citation metadata

Date: July 2015
From: Immunotherapy(Vol. 7, Issue 7)
Publisher: Future Medicine Ltd.
Document Type: Correction notice
Length: 1,449 words
Lexile Measure: 1510L

Document controls

Main content

Article Preview :

In the article: Yiu ZZN & Warren RB. Efficacy and safety of emerging immunotherapies in psoriasis. Immunotherapy 7(2), 119-133 (2015) (www.futuremedicine.com/doi/pdf/10.2217/imt.14.101), the following corrections have been made:

On page 127, the Efficacy paragraph was incorrectly shown as:

Efficacy

Two Phase IIB RCT have been conducted to investigate the efficacy of apremilast in the treatment of chronic plaque psoriasis. The first involved 352 patients randomized to receive different doses of apremilast and placebo [56] . At the primary end point of week 16, PASI 75 was found to be significantly higher in the doses of 20 and 30 mg as compared with placebo (29 and 41%, respectively, placebo 6%). The second study involved 259 patients randomized equally to placebo, 20 mg apremilast once a day and 20 mg twice a day. At the primary end point of week 12, the PASI 75 for the 20 mg BD group was 24.4% and significant better than placebo (10.3%), while the apremilast 20 mg once a day group was not significantly better than placebo (Table 2) . Two Phase III RCTs, ESTEEM 1 and ESTEEM 2 investigated the efficacy of apremilast at a dose of 30 mg bd against placebo. In ESTEEM 1, a study of 844 patients randomized to placebo and treatment arms, the results at the primary end point of 16 weeks showed a significantly higher PASI 75 response of 33.1% in the treatment group, as compared with 5.3% in the placebo group [57] . The ESTEEM 2 trial, a study of 413 patients randomized to placebo and treatment arms, reported significantly higher PASI 75 responses of 28.8% in the treatment arm as compared with 5.8% in the placebo group [58] . In addition to its efficacy for psoriasis, apremilast has also been shown to be effective for the treatment of PsA in a Phase III RCT study PALACE 1, with an significant improvement of clinical severity score for both 20 and 30 mg twice a day doses against placebo [59] .

The correct paragraph is shown below:

Efficacy

Two Phase II RCT have been conducted to investigate the efficacy of apremilast in the treatment of chronic plaque psoriasis. The first involved 259 patients randomized equally to placebo, 20 mg apremilast once a...

Source Citation

Source Citation   

Gale Document Number: GALE|A428994461